Project Grant R21AI187633
Award Date
7/7/25
Completion Date
6/30/27
Dollars Obligated
$386K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $158,000.00 to Rutgers, The State University to conduct research on mechanisms of nitric oxide detoxification and reactivity in the bacterial pathogen Pseudomonas aeruginosa. The research aims to elucidate both the cell-intrinsic regulatory pathways that allow P. aeruginosa to resist nitric oxide toxicity, as well as...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $433,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The funding supports research to investigate the role of the influenza A virus (IAV) protein PB1-F2 in causing hypoxemia (low blood oxygen levels) and acute respiratory distress syndrome (ARDS) in influenza infections. The research aims to define the effects of PB1-F2 on alveolar type II (ATII)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, provides $3,204,624.00 to the University of Pennsylvania to define the molecular and cellular mechanisms of non-canonical inflammasome responses to lipopolysaccharide (LPS) in mice and humans. The goal is to provide essential insight for developing improved therapeutics to reduce human sepsis and enhance immune responses to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $684,206 to the University of Maryland, Baltimore to develop immunomodulatory nanoparticles (INPs) as a novel therapeutic approach to improve outcomes for patients with sepsis. The primary objectives are to: 1) evaluate the immunomodulatory properties of INPs to maximize therapeutic efficacy in a sepsis...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $195,625 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Colorado Boulder. The grant supports research to structurally and functionally characterize phosphoethanolamine (PEtN) transferases, enzymes responsible for conferring resistance to cationic antimicrobial peptides (CAMPs) and the antibiotic colistin in multidrug-resistant Gram-negative...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $707,534 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center. The grant supports research to investigate the mechanisms by which the ZFAND6 protein regulates mitophagy, inflammation, and the NLRP3 inflammasome. The research aims to provide new insights into the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $188,544 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Iowa. The grant will fund research to better understand the molecular mechanisms underlying SARS-CoV-2 infection and innate immune regulation. Specifically, the project aims to examine the role of the protein SAMHD1 in regulating SARS-CoV-2-induced inflammation in primary human airway epithelial cell...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $143,450 to support research on developing therapies for treating viral-induced acute lung injury. The primary focus is on evaluating the therapeutic efficacy of combinations of PPARG agonist and RXR ligand compounds in cotton rat models of influenza and respiratory syncytial virus (RSV) infection. The research...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $171,254 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Nimml Institute Inc., a 501(c)(3) non-profit research organization in Blacksburg, Virginia. The grant, effective from December 1, 2024 to November 30, 2026, aims to elucidate novel immunometabolic mechanisms that intercept bacterial toxin internalization and processing to suppress cell damage caused by Clostridioides difficile...
This federal Project Grant award of $2,976,652 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore polyamine toxicity and resistance in epidemic bacterial skin pathogens, specifically methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes (Group A Streptococcus). The research aims to understand how polyamines enter and kill these bacteria, and how...